Boston Scientific (NYSE:BSX – Get Free Report) was downgraded by stock analysts at TD Cowen from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, MarketBeat reports. They presently have a $46.00 price target on the medical equipment provider’s stock, down from their prior price target of $56.00. TD Cowen‘s price target would indicate a potential upside of 9.71% from the company’s current price.
Other equities analysts have also recently issued reports about the company. Wells Fargo & Company reduced their target price on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday. Truist Financial dropped their price target on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Oppenheimer lowered shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday. Rothschild & Co Redburn cut their price target on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Boston Scientific in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.43.
Read Our Latest Report on Boston Scientific
Boston Scientific Trading Down 1.8%
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter last year, the firm earned $0.75 EPS. Boston Scientific’s quarterly revenue was up 1.4% on a year-over-year basis. As a group, sell-side analysts predict that Boston Scientific will post 3.17 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director David Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael Mahoney purchased 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have acquired 189,522 shares of company stock worth $9,157,810. 0.34% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Boston Scientific
A number of hedge funds have recently added to or reduced their stakes in the business. Bfsg LLC lifted its stake in Boston Scientific by 3.7% in the 3rd quarter. Bfsg LLC now owns 7,867 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 284 shares in the last quarter. Chicago Partners Investment Group LLC grew its stake in Boston Scientific by 293.0% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 179,962 shares of the medical equipment provider’s stock valued at $8,222,000 after acquiring an additional 134,169 shares in the last quarter. Covestor Ltd grew its stake in Boston Scientific by 112.1% during the 3rd quarter. Covestor Ltd now owns 1,968 shares of the medical equipment provider’s stock valued at $86,000 after acquiring an additional 1,040 shares in the last quarter. Richardson Financial Services Inc. increased its holdings in shares of Boston Scientific by 6.0% in the 3rd quarter. Richardson Financial Services Inc. now owns 9,735 shares of the medical equipment provider’s stock valued at $425,000 after purchasing an additional 550 shares during the period. Finally, Ascent Group LLC increased its holdings in shares of Boston Scientific by 29.0% in the 3rd quarter. Ascent Group LLC now owns 48,869 shares of the medical equipment provider’s stock valued at $2,133,000 after purchasing an additional 10,974 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.
Boston Scientific News Summary
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
- Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
- Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
- Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
- Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
- Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
- Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific
Boston Scientific Company Profile
Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.
Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.
Further Reading
- Five stocks we like better than Boston Scientific
- Starbucks Says Its Turnaround Is DoneāThe Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
